Home > Insider Trading > Filing (0000899243-21-018116)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1785530	Werewolf Therapeutics Inc.	HOWL	Pharmaceutical Preparations (2834)	823523180

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1857822	Sakae Asanuma	C/O Werewolf Therapeutics, Inc. 1030 Massachusetts Avenue, Suite 210 Cambridge MA 02138		Yes	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2021-05-04	1,318,311	$0.00	1,318,311	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2021-05-04	438,098	$0.00	1,756,409	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2021-05-04	312,500	$16.00	2,068,909	No	4	P	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See footnote
No	4	C	Indirect	See footnote
No	4	P	Indirect	See footnote

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series B Preferred Stock	Acquisiton	2020-12-23	3,797,921	$0.92	438,098	$0.00
Common Stock	Series A Preferred Stock	Disposition	2021-05-04	11,428,570	$0.00	1,318,311	$0.00
Common Stock	Series B Preferred Stock	Disposition	2021-05-04	3,797,921	$0.00	438,098	$0.00

Remaning Holdings	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
3,797,921	No	4	P	Indirect
0	No	4	C	Indirect
0	No	4	C	Indirect

Footnotes

On May 4, 2021, the Series A Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
The securities reported herein are held by Taiho Ventures, LLC. Sakae Asanuma is the President & CEO of Taiho Ventures, LLC.
On May 4, 2021, the Series B Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
The Series B Preferred Stock was convertible into common stock on a 8.6691-for-one basis into the number of shares of common stock shown in Column 7 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.